The Board is committed in its work to assess and consider potential modifications to its Excessive Price Guidelines (Guidelines) so that they remain effective both in facilitating Board Staff's review of patented drug prices and in promoting voluntary compliance on the part of patentees to ensure that prices of patented medicines sold in Canada are not excessive.

Outreach Presentation – Compendium of Policies, Guidelines and Procedures, June 2009 – Implementation: January 1, 2010; October 28, 2009, Montreal; October 29, 2009, Toronto (PDF)

Interested parties are to file their written submissions with the Secretary of the Board by e-mail at sylvie.dupont@pmprb-cepmb.gc.ca or by mail at:

Communiqué, June 9, 2009
Results of the March 2009 Consultation and the Board´s revised Excessive Price Guidelines, June 2009 (PDF)
Compendium of Policies, Guidelines and Procedures, June 2009 – implementation date: January 1, 2010 (PDF)

Sylvie Dupont
Secretary of the Board
Patented Medicine Prices Review Board
Box L40
Standard Life Centre
333 Laurier Avenue West, Suite 1400
Ottawa ON K1P 1C1
As in previous consultations, all submissions received by the Board will be posted on its Web site.

DRAFT REVISED EXCESSIVE PRICE GUIDELINES - March 2009

View comments received

Notice and Comment – Draft Revised Excessive Price Guidelines (March 2009) (PDF)

Draft Revised Excessive Price Guidelines

View comments received

Latest Update

DISCUSSION PAPER - Options for Possible Changes to the Patented Medicines Regulations, 1994 and the Excessive Price Guidelines (PDF)

View comments received

Working Groups

CGPA/PMPRB WG

Therapeutic Improvement

International Therapeutic Class Comparison

“Making” and “Marketing” (ss. 85(2) of the Patent Act)

Price Tests (WG-PT)

For ease of reference to user, information has been set-up in a chronological order

Board's Bilateral Meetings - September 2007

Stakeholders' Communiqué (PDF) - May 2007

Face-to-Face Meetings - November 2006

Participants Kit
Summary Reports
- Edmonton (PDF)
- Montréal (PDF)
- Toronto (PDF)
- Halifax (PDF)
- Ottawa (PDF)

Discussion Guide (PDF ) - May 2006

View Comments Received (During the Notice and Comment period)

2005 Consultations on the Excessive Price Guidelines

Price Increases for Patented Medicines

Discussion Paper (PDF)
Appendix I (PDF)

Submissions

Patentees
- Abbott Laboratories Ltd. (PDF)
- ALTANA Pharma (PDF)
- AstraZeneca Canada Inc. (PDF)
- Baxter Corporation (PDF)
- Boehringer Ingelheim (PDF)
- Eli Lilly Canada Inc. (PDF)
- Merck Frosst Canada & Co (PDF)
- Novo Nordisk (PDF)
- Pfizer Canada Inc. (PDF)
- Serono Canada Inc. (PDF)
- Wyeth Canada Inc. (PDF)
Provinces
- Ontario Ministry of Health and Long-Term Care, Drug Programs Branch (PDF)
- Saskatchewan - Drug Plan & Extended Benefits (PDF)
Associations
- Rx&D (PDF)
Consultants
- Brogan Inc. (PDF)
- ESI Canada (PDF)
Physicians
- Dr. Joel Lexchin, M.D. (PDF)
Third Party Payers
- Green Shield Canada (PDF)
Patient Advocacy Groups
- Canadian HIV/Aids Legal Network (PDF)

Background